Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (31-40 of 426) with videos related to

Pageof 43
Sort By:
Expert Opinion on Pharmacotherapy|December 3, 2015
Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd lineCamillo Porta, Palma Giglione, Chiara Paglino
Cancer|January 27, 2024
Hepatocellular carcinoma, vascular endothelial growth factor receptors-targeting agents, and hypertension: A much more complicated relationship than expectedCamillo Porta, Francesca Negri, Laura Cosmai
European Urology|December 4, 2014
Steroids in prostate cancer: the jury is still out... and even more confusedCamillo Porta, Sergio Bracarda, Romano Danesi
Journal of Nephrology|September 6, 2015
Renal toxicity of anticancer agents targeting HER2 and EGFRLaura Cosmai, Maurizio Gallieni, Camillo Porta
World Journal of Gastrointestinal Oncology|December 16, 2024
Mixed neuroendocrine non-neuroendocrine tumors: The quest for evidenceMauro Cives, Camillo Porta, Raffaele Palmirotta
Biologics : Targets & Therapy|November 10, 2021
Biological Therapeutic Advances for the Treatment of Advanced Urothelial CancersMimma Rizzo, Patrizia Giannatempo, Camillo Porta
Critical Reviews in Oncology/Hematology|July 8, 2011
Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical reviewCamillo Porta, Cezary Szczylik, Bernard Escudier
BJU International|February 16, 2012
Sorafenib rechalenge in metastatic renal cell carcinomaCamillo Porta, Chiara Paglino, Ilaria Imarisio
Expert Opinion on Biological Therapy|March 30, 2013
From the Zeno's paradoxes to novel immunotherapeutic agents for kidney cancer: moving from an era of wrong premises and conclusions to a better comprehension of immunologyCamillo Porta, Carlo Ganini, Chiara Paglino
Cancer Chemotherapy and Pharmacology|April 26, 2006
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesotheliomaCamillo Porta, Luciano Mutti, Gianfranco Tassi
Pageof 43

Showing results (31-40 of 426) with videos related to

Sort By:
Pageof 43
Expert Opinion on Pharmacotherapy|December 3, 2015
Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd lineCamillo Porta, Palma Giglione, Chiara Paglino
Cancer|January 27, 2024
Hepatocellular carcinoma, vascular endothelial growth factor receptors-targeting agents, and hypertension: A much more complicated relationship than expectedCamillo Porta, Francesca Negri, Laura Cosmai
European Urology|December 4, 2014
Steroids in prostate cancer: the jury is still out... and even more confusedCamillo Porta, Sergio Bracarda, Romano Danesi
Journal of Nephrology|September 6, 2015
Renal toxicity of anticancer agents targeting HER2 and EGFRLaura Cosmai, Maurizio Gallieni, Camillo Porta
World Journal of Gastrointestinal Oncology|December 16, 2024
Mixed neuroendocrine non-neuroendocrine tumors: The quest for evidenceMauro Cives, Camillo Porta, Raffaele Palmirotta
Biologics : Targets & Therapy|November 10, 2021
Biological Therapeutic Advances for the Treatment of Advanced Urothelial CancersMimma Rizzo, Patrizia Giannatempo, Camillo Porta
Critical Reviews in Oncology/Hematology|July 8, 2011
Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical reviewCamillo Porta, Cezary Szczylik, Bernard Escudier
BJU International|February 16, 2012
Sorafenib rechalenge in metastatic renal cell carcinomaCamillo Porta, Chiara Paglino, Ilaria Imarisio
Expert Opinion on Biological Therapy|March 30, 2013
From the Zeno's paradoxes to novel immunotherapeutic agents for kidney cancer: moving from an era of wrong premises and conclusions to a better comprehension of immunologyCamillo Porta, Carlo Ganini, Chiara Paglino
Cancer Chemotherapy and Pharmacology|April 26, 2006
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesotheliomaCamillo Porta, Luciano Mutti, Gianfranco Tassi
Pageof 43